Retatrutide is developed by Eli Lilly and Company, the same company that makes tirzepatide (Zepbound and Mounjaro)
The fiber in avocados can slow digestion, leading to a more gradual release of glucose into the bloodstream
These side effects can be intense enough for an estimated 10% to 20% of patients to stop using GLP-1s, and they tend to be dose dependent meaning that the higher the dose, the more intense or frequent the side effects can be
It helps me keep putting out in-depth guides as this space evolves.
For your convenience, we accept most forms of online payment
In August 2025, Novo Nordisk announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding cirrhosis, in combination with diet and exercise